Tombes MB - Search Results

1

Clinical and biologic effects of combination therapy with gamma-interferon and tumor necrosis factor.

Schiller JH, Witt PL, Storer B, Alberti D, Tombes MB, Arzoomanian R, Brown RR, Proctor RA, Voss SD, Spriggs DR, et al. Schiller JH, et al. Among authors: tombes mb. Cancer. 1992 Jan 15;69(2):562-71. doi: 10.1002/1097-0142(19920115)69:2<562::aid-cncr2820690247>3.0.co;2-0. Cancer. 1992. PMID: 1728387 Clinical Trial.

2

A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by concurrent 120-h continuous infusions.

Bailey H, Wilding G, Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, Grem JL, Spriggs DR. Bailey H, et al. Among authors: tombes mb. Cancer Chemother Pharmacol. 1992;30(4):297-302. doi: 10.1007/BF00686299. Cancer Chemother Pharmacol. 1992. PMID: 1643698 Clinical Trial.

3

Phase I clinical trial of fazarabine as a twenty-four-hour continuous infusion.

Bailey H, Tutsch KD, Arzoomanian RZ, Tombes MB, Alberti D, Bruggink J, Wilding G. Bailey H, et al. Among authors: tombes mb. Cancer Res. 1991 Feb 15;51(4):1105-8. Cancer Res. 1991. PMID: 1705165 Clinical Trial.

4

A phase I study of SR-2508 and cyclophosphamide administered by intravenous injection.

Bailey H, Mulcahy RT, Tutsch KD, Rozental JM, Alberti D, Arzoomanian RZ, Tombes MB, Trump DL, Wilding G. Bailey H, et al. Among authors: tombes mb. Cancer Res. 1991 Feb 15;51(4):1099-104. Cancer Res. 1991. PMID: 1825475 Clinical Trial.

5

Biological and clinical effects of intravenous tumor necrosis factor-alpha administered three times weekly.

Schiller JH, Storer BE, Witt PL, Alberti D, Tombes MB, Arzoomanian R, Proctor RA, McCarthy D, Brown RR, Voss SD, et al. Schiller JH, et al. Among authors: tombes mb. Cancer Res. 1991 Mar 15;51(6):1651-8. Cancer Res. 1991. PMID: 1998956 Clinical Trial.

6

Phase I trial of 5-fluorouracil and dipyridamole administered by seventy-two-hour concurrent continuous infusion.

Remick SC, Grem JL, Fischer PH, Tutsch KD, Alberti DB, Nieting LM, Tombes MB, Bruggink J, Willson JK, Trump DL. Remick SC, et al. Among authors: tombes mb. Cancer Res. 1990 May 1;50(9):2667-72. Cancer Res. 1990. PMID: 2328492

7

Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione.

Bailey HH, Mulcahy RT, Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, Wilding G, Pomplun M, Spriggs DR. Bailey HH, et al. Among authors: tombes mb. J Clin Oncol. 1994 Jan;12(1):194-205. doi: 10.1200/JCO.1994.12.1.194. J Clin Oncol. 1994. PMID: 8270977 Clinical Trial.

8

Phase I clinical and pharmacokinetic study of an one-hour infusion of ormaplatin (NSC 363812).

Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, Feierabend C, Robins HI, Spriggs DR, Wilding G. Tutsch KD, et al. Among authors: tombes mb. Invest New Drugs. 1999;17(1):63-72. doi: 10.1023/a:1006223100561. Invest New Drugs. 1999. PMID: 10555124 Clinical Trial.

9

Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation.

Roberts JD, Poplin EA, Tombes MB, Kyle B, Spicer DV, Grant S, Synold T, Moran R. Roberts JD, et al. Among authors: tombes mb. Cancer Chemother Pharmacol. 2000;45(2):103-10. doi: 10.1007/s002800050017. Cancer Chemother Pharmacol. 2000. PMID: 10663624 Clinical Trial.

10

Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks.

Roberts JD, Shibata S, Spicer DV, McLeod HL, Tombes MB, Kyle B, Carroll M, Sheedy B, Collier MA, Pithavala YK, Paradiso LJ, Clendeninn NJ. Roberts JD, et al. Among authors: tombes mb. Cancer Chemother Pharmacol. 2000;45(5):423-7. doi: 10.1007/s002800051012. Cancer Chemother Pharmacol. 2000. PMID: 10803927 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

31 results

Search Page

Filters